3 Numbers That Make Novavax a Buy Right Now
Novavax (NASDAQ: NVAX) was an early leader in the coronavirus vaccine race. And its shares reflected that. They soared 2,700% in 2020. But last year was a tough one for the company and investors. Novavax fell behind in its regulatory authorization requests, and share gains turned modest compared to the previous year's mind-boggling increase. The stock climbed only 28%.
Today, the situation has changed once again for Novavax -- for the positive. About 38 countries have authorized its coronavirus vaccine, and blockbuster revenue is on the way. Here are three numbers that signal that now is time to buy shares of this vaccine latecomer.
Image source: Getty Images.
Source Fool.com
